After 24 hrs
After 30 days
51-year-old female with a significant wound infection post ankle infusion surgery. Diagnosed with arthritis on her right ankle due to talar avascular necrosis (death of bone tissue due to a lack of blood supply).
Using a rubber bulb, Patient X pushed the mixture up into both the left and right nasal passages, toward the ears. Upon applying R327 in the infected area, Patient X noted a minor stinging sensation as the solution reached the area of infection in both nasal passages, subsiding after approximately three minutes.
Within 90 minutes , Patient X recorded their sinuses began to feel clearer, less inflamed and reported less discharge. As Patient X continued their dosing program, the stinging sensation subsided over time.
Over a three-day period of applying R327 topically via spray to the infected areas in the sinus , Patient X reported a substantial reduction in infected discharge, cessation of sweating and a return to normal sleeping patterns with no side effects. Post-dosing program, blood samples were taken and tested. These samples showed no detectable signs of P. aeruginosa infection and no abnormalities .
Not long after the dosing program, the patient reported feeling a return of the initial infection. Following a sinus biopsy, an opportunistic ‘common bacterium’ had taken residence where the P. aeruginosa was previously. Having advanced from a life- threating infection status, it was agreed that the new, unrelated bacterial infection was early in its growth. A course of Septrim Forte cleared the opportunistic bacteria and the initial drug resistant P. aeruginosa remained undetected.
About RECCE® 327
RECCE® 327 (R327) is a synthetic anti-infective developed for the treatment of serious and potentially life-threatening infections due to
Gram-positive and Gram-negative bacteria, including the full suite of ESKAPE pathogens, even in their superbug forms. R327’s novel
mechanism of action (MOA) is designed to safely enter the body, identify and treat an infection, and exit – with the potential to overcome
R327, as an IV therapy, is being studied in a broad range of bacterial infections.
Preclinical studies have demonstrated R327’s ability to rapidly and irreversibly shut down bacterial cellular energy ATP production, disrupting important functions within the bacteria, leading to:
This multi-layered MOA uniquely allows it to kill bacteria and keep on killing with repeated use, a challenge of all existing antibiotics.